FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

FDA approved a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc., leading to changes to the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

SUPPL AP for COPAXONE (GLATIRAMER ACETATE)